ClinicalTrials.gg
Status unknownNCT00532519Updated Sep 20, 2007

Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

An interventional study of citalopram (cipralex) in Prurigo Nodularis, sponsored by Hadassah Medical Organization. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2007-09-20.

Sponsored by Hadassah Medical Organization · Not applicable and Interventional

The sponsor has not verified this record recently (last verified Sep 2007), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.

02

Conditions studied

  • Prurigo Nodularis

Browse trials for

03

In context

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

Browse Prurigo studies →

Lead sponsor

Hadassah Medical Organization is the lead sponsor of 675 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • prurigo nodularis
  • age: 18-70 years
  • agreed to participate

Exclusion criteria

Exclusion Criteria:

  • younger than 18 or older than 70
  • pregnant or lactating women
  • chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.
  • sensitivity to cipralotam
  • psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year
  • use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine
05

Study design

Phase
Not applicable
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)

Interventions

06

Study locations

1 site
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 20, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00532519
First posted
Sep 20, 2007
Last update
Sep 20, 2007

Study contacts

Liran Horev, MD
Contact
LIRAN_CH@BEZEQINT.NET
OO97226777111
liran horev, md
principal investigator · Hadassah Medical Organization
rena cooper-kazaz, md
principal investigator · Hadassah Medical Organization

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Escitalopram

Start the discussion